Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
#Expand
Jun 1, 2022
www.prnewswire.com
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
#Partners #Acquisition
May 12, 2022
www.prnewswire.com
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
#Acquisition
Jan 31, 2022
www.prnewswire.com
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
#Management Changes
Aug 3, 2020
www.globenewswire.com
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
#Partners
Feb 19, 2020
www.calcalistech.com
Cancer Immunotherapy Startup NeoTX Raises $45 Million
#Investment
Oct 28, 2019
www.globenewswire.com
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
#Partners
Feb 11, 2019
www.globenewswire.com
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
#Partners
Apr 12, 2018
www.globenewswire.com
Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer
#Partners
Oct 26, 2016
www.globenewswire.com
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology
Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
#Expand
Jun 1, 2022
www.prnewswire.com
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
#Partners #Acquisition
May 12, 2022
www.prnewswire.com
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
#Acquisition
Jan 31, 2022
www.prnewswire.com
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
#Management Changes
Aug 3, 2020
www.globenewswire.com
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
#Partners
Feb 19, 2020
www.calcalistech.com
Cancer Immunotherapy Startup NeoTX Raises $45 Million
#Investment
Oct 28, 2019
www.globenewswire.com
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
#Partners
Feb 11, 2019
www.globenewswire.com
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
#Partners
Apr 12, 2018
www.globenewswire.com
Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer
#Partners
Oct 26, 2016
www.globenewswire.com
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology